Reversing the hemoglobin switch

New England Journal of Medicine

Volumn 363, Issue 23, 2010, Pages 2258-2260

  Sankaran, Vijay G ^a   Nathan, David G ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; EPSILON GLOBIN; GAMMA GLOBIN; HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; TRANSCRIPTION FACTOR GATA;

B CELL LYMPHOMA; CHROMOSOME 11; DRUG EFFICACY; ERYTHROPOIESIS; GENE CONTROL; GENE LOCUS; GESTATIONAL AGE; GLOBIN SYNTHESIS; HUMAN; LIVER; NONHUMAN; NONSENSE MUTATION; PREGNANCY; PRIORITY JOURNAL; SHORT SURVEY; SICKLE CELL ANEMIA; SPLEEN; YOLK SAC;

EID: 78649719826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1010767     Document Type: Short Survey

References (5)

1. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008;358:1362-9.
2. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010;42:742-4.
3. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-42.
4. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009;460:1093-7.
5. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010;42:801-5.